Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic CART-33 in Relapsed/Refractory CD33+ AML
NCT02799680Phase 1Unknown
- Sponsor
- 307 Hospital of the People's Liberation Army
- Start
- Oct 2015
- Primary completion
- May 2017
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD33 CAR-T in acute myeloid leukemia (AML), sponsored by 307 Hospital of the People's Liberation Army. Primary endpoint: Occurrence of study related adverse events at 1 year. Status: unknown.
02
Drugs
CD33 CAR-T
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02799680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02799680.